CBDX (Curative Biosciences) Short-Term Debt: $0.16 Mil (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Curative Biosciences Short-Term Debt?

Curative Biosciences CBDX Short-Term Debt is $0.16 Mil as of Mar. 2018.

Curative Biosciences's Short-Term Debt for the quarter that ended in Mar. 2018 was $0.16 Mil.

Curative Biosciences's quarterly Short-Term Debt stayed the same from Sep. 2017 ($0.00 Mil) to Dec. 2017 ($0.00 Mil) but then increased from Dec. 2017 ($0.00 Mil) to Mar. 2018 ($0.16 Mil).

Curative Biosciences's annual Short-Term Debt increased from Jun. 2015 ($0.00 Mil) to Jun. 2016 ($0.05 Mil) and increased from Jun. 2016 ($0.05 Mil) to Jun. 2017 ($0.06 Mil).

Curative Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Curative Biosciences Short-Term Debt Related Terms

Curative Biosciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences Short-Term Debt Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.05 0.06

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.06 0.00 0.00 0.16
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.16 Mil mean?
Curative Biosciences (CBDX) has a Short-Term Debt of $0.16 Mil as of Mar. 2018.
Is Curative Biosciences' Short-Term Debt too high?
Curative Biosciences' current Short-Term Debt is $0.16 Mil.
How does Curative Biosciences' Short-Term Debt compare to ACUR and CVLB?
Curative Biosciences' Short-Term Debt of $0.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Curative Biosciences's current Short-Term Debt is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current Short-Term Debt of $0.16 Mil. The current Short-Term Debt is $0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current Short-Term Debt is $0.16 Mil as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.